| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Laurent Béchard, Mahité Morasse-Bégis, Olivier Corbeil, Joseph-Raymond Hakim, Esthel Malenfant, Sébastien Brodeur, Maxime Huot-Lavoie, Anne-Marie Essiambre, Marie-France Demers, Marc-André Ro. Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series. Journal of clinical psychopharmacology. 2022-05-12. PMID:35546087. |
clozapine is the most efficacious antipsychotic for treatment-resistant schizophrenia. |
2022-05-12 |
2023-08-13 |
human |
| Gentaro Miura, Kouhei Tanaka, Takashi Kemuriyama, Fuminari Misawa, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuch. Clinical Outcomes after Clozapine Discontinuation in Patients with Schizophrenia: A Systematic Review. Pharmacopsychiatry. 2022-05-05. PMID:35512817. |
clinical outcomes after clozapine discontinuation in patients with schizophrenia: a systematic review. |
2022-05-05 |
2023-08-13 |
Not clear |
| Gentaro Miura, Kouhei Tanaka, Takashi Kemuriyama, Fuminari Misawa, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuch. Clinical Outcomes after Clozapine Discontinuation in Patients with Schizophrenia: A Systematic Review. Pharmacopsychiatry. 2022-05-05. PMID:35512817. |
clozapine is the gold standard of treatment for patients with treatment-resistant schizophrenia. |
2022-05-05 |
2023-08-13 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Yuji Yada, Masafumi Kodama, Yoshiki Kishi, Norihito Yamad. Changes in Plasma Clozapine Levels after Smoking Cessation in Japanese Inpatients with Schizophrenia: A Retrospective Cohort Study. Acta medica Okayama. vol 76. issue 2. 2022-05-03. PMID:35503441. |
changes in plasma clozapine levels after smoking cessation in japanese inpatients with schizophrenia: a retrospective cohort study. |
2022-05-03 |
2023-08-13 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Yuji Yada, Masafumi Kodama, Yoshiki Kishi, Norihito Yamad. Changes in Plasma Clozapine Levels after Smoking Cessation in Japanese Inpatients with Schizophrenia: A Retrospective Cohort Study. Acta medica Okayama. vol 76. issue 2. 2022-05-03. PMID:35503441. |
we here investigated plasma clozapine levels before and after smoking cessation in japanese inpatients with schizophrenia. |
2022-05-03 |
2023-08-13 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Yuji Yada, Masafumi Kodama, Yoshiki Kishi, Norihito Yamad. Changes in Plasma Clozapine Levels after Smoking Cessation in Japanese Inpatients with Schizophrenia: A Retrospective Cohort Study. Acta medica Okayama. vol 76. issue 2. 2022-05-03. PMID:35503441. |
we conducted a retrospective chart review of 14 inpatients with schizophrenia who were being treated with clozapine between june 1, 2019, and july 31, 2019 and who were smokers as of july 1, 2019, the day on which a smoking ban was instituted in the tertiary public psychiatric hospital. |
2022-05-03 |
2023-08-13 |
Not clear |
| Amanda Seamon, Reddy Shashan. Improved MOCA Scores While on Clozapine Gains Insight into HIV. CNS spectrums. vol 27. issue 2. 2022-04-28. PMID:35477603. |
the benefit of clozapine treatment for schizophrenia patients with comorbid hiv extends beyond just symptomatic control. |
2022-04-28 |
2023-08-13 |
Not clear |
| Judith Weise, Georg Schomerus, Sven Speerforc. Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 20. issue 2. 2022-04-25. PMID:35466111. |
add-on cariprazine in patients with long-term clozapine treatment and treatment resistant schizophrenia: two cases of psychotic deterioration and pisa syndrome. |
2022-04-25 |
2023-08-13 |
Not clear |
| Ankita Narang, Paul Lacaze, Kathlyn J Ronaldson, John J McNeil, Mahesh Jayaram, Naveen Thomas, Rory Sellmer, David N Crockford, Robert Stowe, Steven C Greenway, Christos Pantelis, Chad A Bousma. Whole-genome sequencing analysis of clozapine-induced myocarditis. The pharmacogenomics journal. 2022-04-24. PMID:35461379. |
one of the concerns limiting the use of clozapine in schizophrenia treatment is the risk of rare but potentially fatal myocarditis. |
2022-04-24 |
2023-08-13 |
human |
| Emma Butler, Toby Pillinger, Kirsten Brown, Faith Borgan, Alice Bowen, Katherine Beck, Enrico D'Ambrosio, Lisa Donaldson, Sameer Jauhar, Stephen Kaar, Tiago Reis Marques, Robert A McCutcheon, Maria Rogdaki, Fiona Gaughran, James MacCabe, Rosalind Ramsay, David Taylor, Paul McCrone, Alice Egerton, Oliver D Howe. Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. The British journal of psychiatry : the journal of mental science. 2022-04-19. PMID:35438068. |
clozapine is the only drug licensed for treatment-resistant schizophrenia (trs) but the real-world clinical and cost-effectiveness of community initiation of clozapine is unclear. |
2022-04-19 |
2023-08-13 |
Not clear |
| Annie Blazer, K N Roy Chengappa, William Foran, Ashley C Parr, Charles E Kahn, Beatriz Luna, Deepak K Sarpa. Changes in corticostriatal connectivity and striatal tissue iron associated with efficacy of clozapine for treatment‑resistant schizophrenia. Psychopharmacology. 2022-04-18. PMID:35435461. |
though numerous studies demonstrate the superiority of clozapine (clz) for treatment of persistent psychotic symptoms that are characteristic of treatment-refractory schizophrenia (trs), what remains unknown are the neural and molecular mechanisms underlying clz's efficacy. |
2022-04-18 |
2023-08-13 |
Not clear |
| Pasindu Wickramarachchi, Jessica M Boyd, Dennis J Orto. Biological Variation in Clozapine and Metabolite Reporting During Therapeutic Drug Monitoring. Clinica chimica acta; international journal of clinical chemistry. 2022-04-10. PMID:35398248. |
clozapine (clo) is an atypical antipsychotic used in management of treatment-resistant schizophrenia. |
2022-04-10 |
2023-08-13 |
Not clear |
| C Okhuijsen-Pfeifer, M Z van der Horst, C A Bousman, B Lin, K R van Eijk, S Ripke, Y Ayhan, M O Babaoglu, M Bak, W Alink, H van Beek, E Beld, A Bouhuis, M Edlinger, I M Erdogan, A Ertuğrul, G Yoca, I P Everall, T Görlitz, K P Grootens, S Gutwinski, T Hallikainen, E Jeger-Land, M de Koning, M Lähteenvuo, S E Legge, S Leucht, C Morgenroth, A Müderrisoğlu, A Narang, C Pantelis, A F Pardiñas, T Oviedo-Salcedo, J Schneider-Thoma, S Schreiter, E Repo-Tiihonen, H Tuppurainen, M Veereschild, S Veerman, M de Vos, E Wagner, D Cohen, J P A M Bogers, J T R Walters, A E Anil Yağcıoğlu, J Tiihonen, A Hasan, J J Luyk. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders. Translational psychiatry. vol 12. issue 1. 2022-04-08. PMID:35393395. |
clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia. |
2022-04-08 |
2023-08-13 |
Not clear |
| Aurélie Lereclus, Théo Korchia, Camille Riff, Frédéric Dayan, Oliver Blin, Sylvain Benito, Romain Guilhaumo. Towards precision dosing of clozapine in schizophrenia: external evaluation of population pharmacokinetic models and Bayesian forecasting. Therapeutic drug monitoring. 2022-04-06. PMID:35385439. |
towards precision dosing of clozapine in schizophrenia: external evaluation of population pharmacokinetic models and bayesian forecasting. |
2022-04-06 |
2023-08-13 |
Not clear |
| Jing Sun, Rongsen Zeng, Yunxi Liu, Siyu Xi, Tingkai Sun, Jinjun Qian, Zhenghui Yi, Shengying Qi. Generation of ultra-treatment-resistant schizophrenia patient-derived induced pluripotent stem cell line UJSi002-A. Stem cell research. vol 61. 2022-04-03. PMID:35367693. |
among them, the failure to respond to clozapine full-scale treatment is ultra-treatment-resistant schizophrenia. |
2022-04-03 |
2023-08-13 |
Not clear |
| Antonija Medić, Dora Herceg, Miroslav Herce. Treatment of Resistant and Ultra Resistant Schizophrenia. Psychiatria Danubina. vol 33. issue Suppl 4. 2022-03-30. PMID:35354175. |
clozapine is the golden standard in the treatment of therapy-resistant schizophrenia. |
2022-03-30 |
2023-08-13 |
Not clear |
| Jing Yi Kwan, Maha Noo. Clozapine-induced pulmonary embolism in a patient with no pre-existing risk factors: A case report. Clinical case reports. vol 10. issue 3. 2022-03-28. PMID:35340632. |
we report the case of a 51-year-old caucasian woman who developed a pulmonary embolism in the absence of any pre-existing risk factors for vte, 3 weeks following clozapine initiation for treatment resistant paranoid schizophrenia. |
2022-03-28 |
2023-08-13 |
Not clear |
| Ahmed Naguy, Reda Rushdy, Saxby Pridmore, Anubhuti Singh, Bibi Alamir. Successful Add-on Viloxazine to Clozapine-Responsive Schizophrenia Mitigated Cognitive, Negative and Metabolic Domains. Psychopharmacology bulletin. vol 52. issue 1. 2022-03-28. PMID:35342203. |
here, authors report on an adolescent case with schizophrenia that responded ultimately to clozapine. |
2022-03-28 |
2023-08-13 |
Not clear |
| Andrea Aguglia, Valentina Maria Parisi, Gabriele Arduino, Andrea Amerio, Alessandra Costanza, Gianluca Serafini, Mario Amor. Clozapine in a Young Female with Drug-Resistant Schizophrenia: A Case Report of Development of Serositis. CNS & neurological disorders drug targets. 2022-03-25. PMID:35331125. |
clozapine in a young female with drug-resistant schizophrenia: a case report of development of serositis. |
2022-03-25 |
2023-08-13 |
Not clear |
| Andrea Aguglia, Valentina Maria Parisi, Gabriele Arduino, Andrea Amerio, Alessandra Costanza, Gianluca Serafini, Mario Amor. Clozapine in a Young Female with Drug-Resistant Schizophrenia: A Case Report of Development of Serositis. CNS & neurological disorders drug targets. 2022-03-25. PMID:35331125. |
clozapine may be considered the first-line option for treatment-resistant schizophrenia (trs), a condition that occurs in more than 30% of patients with schizophrenia. |
2022-03-25 |
2023-08-13 |
Not clear |